Gemcitabine Hydrochloride

盐酸吉西他滨

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameGemcitabine Hydrochloride
Drug Alias Name盐酸吉西他宾吉西他滨盐酸盐吉西他滨Gemzar健择 +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA inhibitors
TargetsDNARibonucleotide reductase
Therapy Area/IndicationsBone metastasesMetastatic breast cancerSkin Melanoma +[57] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[7] 
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Original Approved Country/TerritorySouth Africa
Original Approved Date1995/01/10
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of The West Indies, Mona CampusJohnson & Johnson (China) Investment LtdUniversity of Texas Southwestern Medical Center +[20] 
Inactive CompaniesCross Cancer InstituteDana-Farber Cancer InstituteInnopharmax Inc +[43] 
Active IndicationsSkin MelanomaNeoplasms, Multiple PrimaryUrinary Bladder Neoplasms +[28] 
Inactive IndicationsBone metastasesMetastatic breast cancerSolid tumours +[29] 

Other Information

ATC CodeL01BC05
Related LinksWikipediaDrugBankKEGG